Skip to content
DataLookout
Menu

FIRE-12NCT07844057

First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 1, 2026 to Oct 22, 2026
    • Secondary endpoints: 4 to 5
    • Site details revised at 16 of 16 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Median Progression-free survival (PFS)
Timeframe: 84 months

Secondary (5)

Median Overall survival (OS)
Objective response rate (ORR)
Patient Safety
Quality of life (QoL)
Depth of response (DpR),

Arms and interventions

Treatment arm A: mFOLFIRINOX every two weeksOther

* oxaliplatin 85 mg/m² 2 hours intravenously * irinotecan 150 mg/m² 60-90 minutes intravenously * leucovorin 400 mg/m² 2 hours intravenously * 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion

Treatment arm B: FOLFOX every two weeksOther

* oxaliplatin 85 mg/m² 2 hours intravenously * leucovorin 400 mg/m² 2 hours intravenously * 5-fluorouracil 400 mg/m² intravenous bolus injection * 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion

Drugs: mFOLFIRINOX versus FOLFOX chemotherapy

Sites

16 sites in 1 country